Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02235454 · ClinicalTrials.gov registry record · NA

SDOCT-GMPE Software

A NA study of Glaucoma, sponsored by Duke University.

Completed
Registry status
NA
Development phase
57
Enrollment target
1
Study location

NCT02235454: Completed NA study of Glaucoma, sponsored by Duke University.

NCT02235454 is a NA study of Glaucoma that has completed, run by Duke University. The registered enrollment target is 57 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02235454, a NA study of Glaucoma, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
57 participants
Enrollment target
1
Study location

Study Summary

The investigators prospectively evaluate the new glaucoma premium edition (GMPE) software for spectral domain optical coherence tomography (SDOCT) and if this software is superior to the conventional one that is currently used for SDOCT.

Primary Outcome

Pearson correlation coefficient between Retinal Nerve Fiber Layer (RNFL) thickness correlation width global Bruch's membrane opening-minimum rim width (BMO-MRW).

Conditions Studied

Interventions

  • DEVICE SDOCT-GMPE software

Study Locations (1)

North Carolina

  • Duke Eye Center - Durham

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2014-11
Est. Completion 2016-08-01
Phase NA
Duke University

1,725 total trials

What the finished NCT02235454 record still lists

NCT02235454 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which SDOCT-GMPE software is the first listed.

NCT02235454 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT02235454 about?

NCT02235454 is a clinical study titled "SDOCT-GMPE Software". The investigators prospectively evaluate the new glaucoma premium edition (GMPE) software for spectral domain optical coherence tomography (SDOCT) and if this software is superior to the conventional one that is currently used for SDOCT.

What is the current status of trial NCT02235454?

This trial is currently completed. It is a NA study. The enrollment target is 57 participants. The study started on 2014-11. Estimated completion is 2016-08-01.

What conditions does trial NCT02235454 study?

This clinical trial studies the following conditions: Glaucoma.

What interventions are being tested in trial NCT02235454?

The interventions under investigation include: SDOCT-GMPE software (DEVICE).

Who is sponsoring clinical trial NCT02235454?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02235454 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glaucoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02235454's enrollment target sits among peer trials

57 61st of 92 higher than 31 of 92 other Glaucoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03521830 · 57 participants · Phase 2

    Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

  • NCT03587701 · 57 participants · Phase 2

    Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

  • NCT04104126 · 57 participants · NA

    Blood Flow Restriction Therapy in Achilles Injury

  • NCT04703842 · 57 participants · Phase 1

    Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02235454, the US trial registry maintained by the National Library of Medicine. NCT02235454 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.